LANSING, Mich. — Emergent BioSolutions announced the dedication of a $75 million vaccine production facility for its BioDefense Operations in a ceremony July 21, 2006, at its campus here.
Gov. Jennifer Granholm and officials including Maj. Gen. Stephen Reeves, the executive officer for the Department of Defense Joint Program for Chemical and Biological Defense, attended the cornerstone ceremony.
“This building represents a major investment in our biodefense business, and significantly expands our core manufacturing capabilities,” said Fuad El-Hibri, chairman and CEO of Emergent BioSolutions. “When we purchased this facility from the state in 1998, we could only dream of being where we are today. With the support of our employees, our customers, the city of Lansing, and the state of Michigan, that dream is now a reality.”
The new 50,000-square-foot facility is designed to enable the company to expand production of its current product, BioThrax (Anthrax Vaccine Adsorbed), and will provide the potential opportunity for production of other products in the company’s pipeline. Construction of this facility began in February 2006 and is scheduled for completion in 2007. The company expects to initiate manufacturing here in 2008.
BioThrax is the only FDA-approved anthrax vaccine.
Emergent BioSolutions Inc., formed in 2004, is dedicated to the research, development and manufacture of products that harness the immune system to treat and prevent disease. These include vaccines and related products for prophylactic and therapeutic use against common infectious diseases and biological weapons of mass destruction.